20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Modulation of three key innate immune pathways for the most common retinal degenerative diseases

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This review highlights the role of three key immune pathways in the pathophysiology of major retinal degenerative diseases including diabetic retinopathy, age‐related macular degeneration, and rare retinal dystrophies. We first discuss the mechanisms how loss of retinal homeostasis evokes an unbalanced retinal immune reaction involving responses of local microglia and recruited macrophages, activity of the alternative complement system, and inflammasome assembly in the retinal pigment epithelium. Presenting these key mechanisms as complementary targets, we specifically emphasize the concept of immunomodulation as potential treatment strategy to prevent or delay vision loss. Promising molecules are ligands for phagocyte receptors, specific inhibitors of complement activation products, and inflammasome inhibitors. We comprehensively summarize the scientific evidence for this strategy from preclinical animal models, human ocular tissue analyses, and clinical trials evolving in the last few years.

          Related collections

          Most cited references276

          • Record: found
          • Abstract: found
          • Article: not found

          How to interpret LC3 immunoblotting.

          Microtubule-associated protein light chain 3 (LC3) is now widely used to monitor autophagy. One approach is to detect LC3 conversion (LC3-I to LC3-II) by immunoblot analysis because the amount of LC3-II is clearly correlated with the number of autophagosomes. However, LC3-II itself is degraded by autophagy, making interpretation of the results of LC3 immunoblotting problematic. Furthermore, the amount of LC3 at a certain time point does not indicate autophagic flux, and therefore, it is important to measure the amount of LC3-II delivered to lysosomes by comparing LC3-II levels in the presence and absence of lysosomal protease inhibitors. Another problem with this method is that LC3-II tends to be much more sensitive to be detected by immunoblotting than LC3-I. Accordingly, simple comparison of LC3-I and LC3-II, or summation of LC3-I and LC3-II for ratio determinations, may not be appropriate, and rather, the amount of LC3-II can be compared between samples.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inferences, questions and possibilities in Toll-like receptor signalling.

            The Toll-like receptors (TLRs) are the key proteins that allow mammals--whether immunologically naive or experienced--to detect microbes. They lie at the core of our inherited resistance to disease, initiating most of the phenomena that occur in the course of infection. Quasi-infectious stimuli that have been used for decades to study inflammatory mechanisms can activate the TLR family of proteins. And it now seems that many inflammatory processes, both sterile and infectious, may depend on TLR signalling. We are in a good position to apply our understanding of TLR signalling to a range of challenges in immunology and medicine.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Minocycline: far beyond an antibiotic.

              Minocycline is a second-generation, semi-synthetic tetracycline that has been in therapeutic use for over 30 years because of its antibiotic properties against both gram-positive and gram-negative bacteria. It is mainly used in the treatment of acne vulgaris and some sexually transmitted diseases. Recently, it has been reported that tetracyclines can exert a variety of biological actions that are independent of their anti-microbial activity, including anti-inflammatory and anti-apoptotic activities, and inhibition of proteolysis, angiogenesis and tumour metastasis. These findings specifically concern to minocycline as it has recently been found to have multiple non-antibiotic biological effects that are beneficial in experimental models of various diseases with an inflammatory basis, including dermatitis, periodontitis, atherosclerosis and autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease. Of note, minocycline has also emerged as the most effective tetracycline derivative at providing neuroprotection. This effect has been confirmed in experimental models of ischaemia, traumatic brain injury and neuropathic pain, and of several neurodegenerative conditions including Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis and spinal cord injury. Moreover, other pre-clinical studies have shown its ability to inhibit malignant cell growth and activation and replication of human immunodeficiency virus, and to prevent bone resorption. Considering the above-mentioned findings, this review will cover the most important topics in the pharmacology of minocycline to date, supporting its evaluation as a new therapeutic approach for many of the diseases described herein. © 2013 The Authors. British Journal of Pharmacology © 2013 The British Pharmacological Society.
                Bookmark

                Author and article information

                Contributors
                thomas.langmann@uk-koeln.de
                Journal
                EMBO Mol Med
                EMBO Mol Med
                10.1002/(ISSN)1757-4684
                EMMM
                embomm
                EMBO Molecular Medicine
                John Wiley and Sons Inc. (Hoboken )
                1757-4676
                1757-4684
                17 September 2018
                October 2018
                : 10
                : 10 ( doiID: 10.1002/emmm.v10.10 )
                : e8259
                Affiliations
                [ 1 ] Laboratory for Experimental Immunology of the Eye Department of Ophthalmology University of Cologne Cologne Germany
                [ 2 ] Department of Ophthalmology University of Bonn Bonn Germany
                [ 3 ] Centre for Experimental Medicine The Wellcome‐Wolfson Institute for Experimental Medicine School of Medicine, Dentistry & Biomedical Sciences Queen's University Belfast Belfast UK
                [ 4 ] Center for Molecular Medicine University of Cologne Cologne Germany
                Author notes
                [*] [* ]Corresponding author. Tel: +49 221 478 7324; Fax: +49 221 478 84591; E‐mail: thomas.langmann@ 123456uk-koeln.de
                [†]

                These authors contributed equally to this work

                Author information
                http://orcid.org/0000-0003-2280-925X
                http://orcid.org/0000-0001-6826-529X
                Article
                EMMM201708259
                10.15252/emmm.201708259
                6180304
                30224384
                e5c4fc6b-334f-440c-baae-b07f069184af
                © 2018 The Authors. Published under the terms of the CC BY 4.0 license

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 04 January 2018
                : 21 August 2018
                : 31 August 2018
                Page count
                Figures: 4, Tables: 0, Pages: 27, Words: 25353
                Funding
                Funded by: Diabetes UK
                Award ID: 11/0004230
                Award ID: 13/0004729
                Funded by: Deutsche Forschungsgemeinschaft (DFG)
                Award ID: LA1203/6‐2
                Award ID: LA1203/9‐1
                Award ID: LA1203/10‐1
                Award ID: FOR2240
                Funded by: Pro Retina Foundation
                Funded by: Hans and Marlies Stock Foundation
                Funded by: European Union Horizon 2020
                Award ID: 722717
                Funded by: Fight for Sight UK
                Award ID: 1574/1575
                Funded by: Dunhill Medical Trust (DMT)
                Award ID: R188/0211
                Categories
                Review
                Review
                Custom metadata
                2.0
                emmm201708259
                October 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.0.1 mode:remove_FC converted:11.10.2018

                Molecular medicine
                complement,inflammasome,microglia,mononuclear phagocytes,retina,immunology,neuroscience
                Molecular medicine
                complement, inflammasome, microglia, mononuclear phagocytes, retina, immunology, neuroscience

                Comments

                Comment on this article